A recent study published in the journal Nature Medicine evaluated the effects of semaglutide with and without the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLT2i) in people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Study: Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial . Image Credit: Caroline Ruda / Shutterstock People with CKD or T2D are at high risk for cardiovascular complications and kidney failure.
Preliminary trials with SGLT2i and glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) in those with high cardiovascular risk and T2D were powered for cardiovascular outcomes. Some of these trials revealed benefits for both drug classes. The “Evaluate Renal Function with Semaglutide Once Weekly” (FLOW) trial was the first trial with dedicated kidney outcomes in people with CKD and T2D.
The trial revealed clear benefits of semaglutide treatment on kidney and cardiovascular outcomes and survival. GLP-1 RAs are substantially beneficial for CKD or cardiovascular outcomes, heart failure, and death. Likewise, SGLT2i are also effective in preventing heart failure and cardiovascular outcomes.
A combination of both drug classes might further augment clinical outcomes. However, no study has examined the effects of the two drug classes on cardiovascular and kidney outcomes in those with CKD and T2D. In the present study, researchers evalu.
